Truist Financial Upgrades Compugen (NASDAQ:CGEN) to “Strong-Buy”

Compugen (NASDAQ:CGEN) was upgraded by equities researchers at Truist Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, January 21st. Finally, HC Wainwright assumed coverage on Compugen in a research note on Wednesday, January 7th. They set a “buy” rating and a $4.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Compugen Stock Performance

NASDAQ:CGEN opened at $2.06 on Wednesday. The company has a market cap of $194.77 million, a PE ratio of 5.57 and a beta of 2.90. Compugen has a twelve month low of $1.13 and a twelve month high of $2.38. The company’s 50 day moving average is $1.97 and its two-hundred day moving average is $1.74.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The business had revenue of $67.33 million for the quarter, compared to analyst estimates of $14.30 million. As a group, analysts expect that Compugen will post -0.03 EPS for the current fiscal year.

Institutional Trading of Compugen

A number of hedge funds and other institutional investors have recently made changes to their positions in CGEN. Franklin Resources Inc. acquired a new position in Compugen during the second quarter valued at $56,000. Jane Street Group LLC boosted its holdings in Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 359,785 shares during the last quarter. Renaissance Technologies LLC grew its position in Compugen by 3.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after purchasing an additional 51,565 shares during the period. State Street Corp grew its position in Compugen by 3.9% during the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 14,701 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 18,929 shares during the last quarter. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.